Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
- Author
- ReachMD
- Published
- Mon 23 Dec 2024
- Episode Link
- https://reachmd.com/programs/frontlines-non-small-cell-lung-cancer/analyzing-dato-dxd-for-non-squamous-nsclc-with-brain-metastases/26242/
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.
